Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Neglected Tropical Disease Treatment Market, By Disease
7.1. Neglected Tropical Disease Treatment Market, By Disease, 2021-2028
7.1.1. Dengue
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Rabies
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Trachoma
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Buruli Ulcer
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Yaws
7.1.5.1. Market Revenue and Forecast (2016-2028)
7.1.6. Leprosy
7.1.6.1. Market Revenue and Forecast (2016-2028)
7.1.7. Chagas Disease
7.1.7.1. Market Revenue and Forecast (2016-2028)
7.1.8. Human African Trypanosomiasis (Sleeping Sickness)
7.1.8.1. Market Revenue and Forecast (2016-2028)
7.1.9. Leishmaniases
7.1.9.1. Market Revenue and Forecast (2016-2028)
7.1.10. Soil-Transmitted Helminthiases
7.1.10.1. Market Revenue and Forecast (2016-2028)
7.1.11. Others
7.1.11.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Neglected Tropical Disease Treatment Market, Product Type
8.1. Neglected Tropical Disease Treatment Market, Product Type, 2021-2028
8.1.1. Drugs
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Neglected Tropical Disease Treatment Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Disease (2016-2028)
9.1.2. Market Revenue and Forecast, Product Type (2016-2028)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.1.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.1.4.2. Market Revenue and Forecast, Product Type (2016-2028)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Disease (2016-2028)
9.2.2. Market Revenue and Forecast, Product Type (2016-2028)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.2.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.2.4.2. Market Revenue and Forecast, Product Type (2016-2028)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Disease (2016-2028)
9.2.5.2. Market Revenue and Forecast, Product Type (2016-2028)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Disease (2016-2028)
9.2.6.2. Market Revenue and Forecast, Product Type (2016-2028)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.3.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.3.4.2. Market Revenue and Forecast, Product Type (2016-2028)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Disease (2016-2028)
9.3.5.2. Market Revenue and Forecast, Product Type (2016-2028)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Disease (2016-2028)
9.3.6.2. Market Revenue and Forecast, Product Type (2016-2028)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.4.2. Market Revenue and Forecast, Product Type (2016-2028)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.4.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.4.4.2. Market Revenue and Forecast, Product Type (2016-2028)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Disease (2016-2028)
9.4.5.2. Market Revenue and Forecast, Product Type (2016-2028)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Disease (2016-2028)
9.4.6.2. Market Revenue and Forecast, Product Type (2016-2028)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Disease (2016-2028)
9.5.2. Market Revenue and Forecast, Product Type (2016-2028)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Disease (2016-2028)
9.5.3.2. Market Revenue and Forecast, Product Type (2016-2028)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Disease (2016-2028)
9.5.4.2. Market Revenue and Forecast, Product Type (2016-2028)
Chapter 10. Company Profiles
10.1. F. Hoffmann-La Roche Ltd
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Bayer AG
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. GlaxoSmithKline plc
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Novartis AG
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Pfizer, Inc.
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Eisai Co. Ltd.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Sanofi
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Astellas Pharma
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Takeda Pharmaceutical Company Limited
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Gilead Sciences
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms